MedTrace Logo

Phase I Clinical Trial of a Candidate Herpes Zoster Vaccine

NCT05718037 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-02-08

No results posted yet for this study

Summary

This is a phase I, randomized, observer-blinded study to evaluate the safety, tolerability, and immunogenicity of BV211(a herpes zoster vaccine) in Adult Volunteers.

Conditions

  • Herpes Zoster

Interventions

BIOLOGICAL

Recombinant Zoster Vaccine

0.5mL, Intramuscular

BIOLOGICAL

Placebo

0.5mL, Intramuscular

BIOLOGICAL

Zoster Vaccine Recombinant, Adjuvanted

0.5mL, Intramuscular

Sponsors & Collaborators

  • Shanghai BravoBio Co., Ltd.

    collaborator UNKNOWN

  • Wuhan BravoVax Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-08-01
Primary Completion
2024-01-31
Completion
2024-07-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05718037 on ClinicalTrials.gov